BYSINasdaq

BeyondSpring Inc.

Healthcare·Oncology·Phase 3·Florham Park, NJ, United States
Oncology

BeyondSpring Inc. (BYSI): 2 pipeline candidates · ~9 mo cash runway · 1 clinical trial. Updated within the last hour.

6.4/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway2.4

8.6 months

Financial Health10.0

D/E -1.41 · 0% dilution

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for BeyondSpring Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$65.4M

Cash

$4.0M

Quarterly Burn

$3.3M

Runway

8.6 mo

Revenue

$0

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Mar 2027
Today~9 mo out
Catalyst within runway

Pipeline (2 candidates)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

18

Total value held

$4.5M

HolderSharesValue
vanguard capital management llc1,215,868$2.0M
blackrock, inc.649,462$1.1M
geode capital management, llc375,371$616K
state street corp231,120$379K
vanguard fiduciary trust co179,925$295K
northern trust corp69,268$114K
susquehanna international group, llp22,300$37K
renaissance technologies llc11,100$18K
morgan stanley4,570$7K
national bank of canada /fi/2,875$5K

Showing top 10 of 18 institutional holders of BeyondSpring Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

1 clinical trial·CEO: Dr. Lan Huang Ph.D.

Frequently asked questions

How many drug candidates are in BeyondSpring Inc.'s pipeline?

BeyondSpring Inc. (BYSI) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is BeyondSpring Inc.'s lead drug candidate?

BeyondSpring Inc.'s most advanced tracked candidate is Plinabulin (Phase 3) for Second- and third-line non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) wild type after progression on prior immune checkpoint inhibitors.

What is BeyondSpring Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, BeyondSpring Inc. has approximately 8.6 months of cash runway.

What is BeyondSpring Inc.'s market capitalization?

BeyondSpring Inc.'s market capitalization is approximately $65.4M.

Who is the CEO of BeyondSpring Inc.?

Dr. Lan Huang Ph.D. is the chief executive officer of BeyondSpring Inc. (BYSI).

Get the full picture on BeyondSpring Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.